Response Genetics announced this week that it has begun gene-expression screening studies for a Phase III trial of GlaxoSmithKline's investigational MAGE-A3 antigen-specific immunotherapeutic for non-small cell lung cancer.
GSK is studying the drug as an adjuvant therapy in MAGE-A3-positive patients with stage IB, II, or IIIA NSCLC. Approximately 35 percent to 50 percent of early NSCLC patients express the MAGE-A3 tumor-specific antigen.